PE20242107A1 - Conjugados que comprenden fosforo (v) y una fraccion molecular de droga - Google Patents
Conjugados que comprenden fosforo (v) y una fraccion molecular de drogaInfo
- Publication number
- PE20242107A1 PE20242107A1 PE2024001005A PE2024001005A PE20242107A1 PE 20242107 A1 PE20242107 A1 PE 20242107A1 PE 2024001005 A PE2024001005 A PE 2024001005A PE 2024001005 A PE2024001005 A PE 2024001005A PE 20242107 A1 PE20242107 A1 PE 20242107A1
- Authority
- PE
- Peru
- Prior art keywords
- dotted line
- bond
- double bond
- conjugates
- phosphorus
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 title 1
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- -1 alkylene glycol Chemical compound 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001515 polyalkylene glycol Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
- C07F9/4461—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4476—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aromatic amines (N-C aromatic linkage)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21207195 | 2021-11-09 | ||
| PCT/EP2022/081345 WO2023083900A1 (en) | 2021-11-09 | 2022-11-09 | Conjugates comprising a phosphorus (v) and a drug moiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20242107A1 true PE20242107A1 (es) | 2024-10-28 |
Family
ID=78592631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001005A PE20242107A1 (es) | 2021-11-09 | 2022-11-09 | Conjugados que comprenden fosforo (v) y una fraccion molecular de droga |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230330258A1 (enExample) |
| EP (1) | EP4429708A1 (enExample) |
| JP (1) | JP2024540691A (enExample) |
| KR (1) | KR20240100413A (enExample) |
| CN (1) | CN118302197A (enExample) |
| AU (1) | AU2022385379A1 (enExample) |
| CA (1) | CA3237371A1 (enExample) |
| CL (1) | CL2024001372A1 (enExample) |
| CO (1) | CO2024005877A2 (enExample) |
| DE (1) | DE22817174T1 (enExample) |
| ES (1) | ES2999335T1 (enExample) |
| IL (1) | IL312675A (enExample) |
| MX (1) | MX2024005546A (enExample) |
| PE (1) | PE20242107A1 (enExample) |
| WO (1) | WO2023083900A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4637832A1 (en) * | 2022-12-22 | 2025-10-29 | Tubulis GmbH | Conjugates comprising a phosphorus(v) moiety and a drug |
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| AU2024332412A1 (en) | 2023-09-01 | 2026-03-12 | Tubulis Gmbh | Methods of preparing phosphonamidate compounds |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| US12521446B2 (en) | 2024-02-27 | 2026-01-13 | Bristol-Myers Squibb Company | Anti-CEACAM5 antibody drug conjugates |
| WO2025262641A1 (en) | 2024-06-19 | 2025-12-26 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US633410A (en) | 1898-09-22 | 1899-09-19 | George A Ames | Ice-cutter. |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| JP2763020B2 (ja) | 1995-04-27 | 1998-06-11 | 日本電気株式会社 | 半導体パッケージ及び半導体装置 |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| EP0964702B1 (en) | 1996-08-02 | 2006-10-04 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| NZ610239A (en) | 2008-04-30 | 2014-11-28 | Immunogen Inc | Cross-linkers and their uses |
| NZ758049A (en) | 2013-10-15 | 2024-03-22 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
| AU2017320913B2 (en) | 2016-09-01 | 2024-08-15 | Forschungsverbund Berlin E.V. | Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates |
| KR102772724B1 (ko) | 2018-03-07 | 2025-02-24 | 포슝스베르분드 베를린 에.베. | 알켄 또는 알킨-포스포노티올레이트 및 -포스포네이트로의 화학선택적 티올-접합 |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
-
2022
- 2022-11-09 WO PCT/EP2022/081345 patent/WO2023083900A1/en not_active Ceased
- 2022-11-09 EP EP22817174.0A patent/EP4429708A1/en active Pending
- 2022-11-09 AU AU2022385379A patent/AU2022385379A1/en active Pending
- 2022-11-09 CN CN202280074835.4A patent/CN118302197A/zh active Pending
- 2022-11-09 JP JP2024549576A patent/JP2024540691A/ja active Pending
- 2022-11-09 DE DE22817174.0T patent/DE22817174T1/de active Pending
- 2022-11-09 IL IL312675A patent/IL312675A/en unknown
- 2022-11-09 KR KR1020247019065A patent/KR20240100413A/ko active Pending
- 2022-11-09 PE PE2024001005A patent/PE20242107A1/es unknown
- 2022-11-09 CA CA3237371A patent/CA3237371A1/en active Pending
- 2022-11-09 US US18/054,018 patent/US20230330258A1/en not_active Abandoned
- 2022-11-09 ES ES22817174T patent/ES2999335T1/es active Pending
- 2022-11-09 MX MX2024005546A patent/MX2024005546A/es unknown
-
2024
- 2024-05-06 CO CONC2024/0005877A patent/CO2024005877A2/es unknown
- 2024-05-06 CL CL2024001372A patent/CL2024001372A1/es unknown
-
2025
- 2025-05-14 US US19/207,970 patent/US20250281634A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023083900A1 (en) | 2023-05-19 |
| US20230330258A1 (en) | 2023-10-19 |
| CL2024001372A1 (es) | 2024-10-25 |
| KR20240100413A (ko) | 2024-07-01 |
| ES2999335T1 (en) | 2025-02-25 |
| IL312675A (en) | 2024-07-01 |
| DE22817174T1 (de) | 2024-12-12 |
| CN118302197A (zh) | 2024-07-05 |
| CA3237371A1 (en) | 2023-05-19 |
| JP2024540691A (ja) | 2024-10-31 |
| US20250281634A1 (en) | 2025-09-11 |
| MX2024005546A (es) | 2024-07-10 |
| EP4429708A1 (en) | 2024-09-18 |
| CO2024005877A2 (es) | 2024-07-08 |
| AU2022385379A1 (en) | 2024-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20242107A1 (es) | Conjugados que comprenden fosforo (v) y una fraccion molecular de droga | |
| PE20242114A1 (es) | Conjugados que comprenden fosforo (v) y una fraccion molecular de camptotecina | |
| JP5557746B2 (ja) | 生体適合性生分解性フマギリンアナログ複合体 | |
| PE20241299A1 (es) | Derivados de exatecan y sus conjugados anticuerpo-farmaco | |
| AR126701A1 (es) | Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos | |
| IL263973A (en) | Protein-polymer-drug couplings | |
| ES2257756T3 (es) | Nuevos profarmacos para la terapia de tumores y enfermedades inflamatorias. | |
| AR067182A1 (es) | Moduladores del receptor 7 tipo toll | |
| KR20150085808A (ko) | 약물 단백질 결합체 | |
| NZ588851A (en) | Potent conjugates and hydrophilic linkers | |
| AR117657A1 (es) | Conjugados de fármaco que comprenden anticuerpos y derivados de ecteinascidina | |
| MX2025007838A (es) | Enlazadores, enlazadores de farmacos y conjugados de los mismos y metodos de uso de los mismos | |
| RU2018120696A (ru) | Конъюгаты анти-cd22 антитело-майтансин и способы их применения | |
| ECSP22088584A (es) | Conjugados de anticuerpos de fármacos | |
| PE20251067A1 (es) | Conjugado anticuerpo-farmaco msln | |
| ES2683168T3 (es) | Secuencia de escisión específica de MMP-14 | |
| JP5649647B2 (ja) | 酸に不安定なトリガーユニット | |
| CN111328333B (zh) | 一种酸法制备抗体药物偶联物中间体的方法及其应用 | |
| MX2026001691A (es) | Conjugados que comprenden enlazadores escindibles | |
| AR134574A1 (es) | Compuesto enlazador modular para conjugados de fármacos de unión a dianas | |
| CA3203849A1 (en) | Dual-cleavage ester linkers for antibody-drug conjugates | |
| WO2023006782A1 (en) | Conjugating reagents and conjugates thereof | |
| PE20252273A1 (es) | Enlazadores novedosos para el suministro sostenido de terapeuticos | |
| CA2562572A1 (en) | Camptothecin derivatives conjugated in position 20 with integrin antagonists | |
| TW202617991A (zh) | 脂質—聚核酸結合物組合物及其用途 |